Insecticides IndiaQ2 FY25

Insecticides India Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹545.5P/E: 13.0Market Cap: ₹1.6K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4
  • Company expects growth in both domestic and international markets, especially from biological products, with ongoing small launches in this segment.
  • Around half a dozen new product launches are lined up in the next 12-18 months, including 4 slated for the current month.
  • Growth in premium (Maharatna) products is a key focus, with about 10% volume growth already seen; generics are being rationalized.
  • Export order book is strong with over INR100 crores in orders, signaling good export market recovery.
  • B2C segment expected to grow; B2B and international business showing initial signs of improvement.
  • Despite some sales return due to weather-related challenges, company aims to compensate with new product introductions in the second half.
  • Outlook for full-year FY25 growth may see some moderation but company targets growth in both top line and bottom line.
  • Improved operational efficiencies and strengthening of brand "Tractor" expected to drive growth.

See what Insecticides India management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or future fundraising plans through debt or equity for Insecticides India Limited. Key points related to financial strategy noted are: - Focus on disciplined financial management and value creation. - Improvement in working capital days from 151 days in March 2024 to 102 days in September 2024. - Emphasis on strengthening R&D, manufacturing, marketing, and product launches without explicit mention of raising funds. - No references to planned equity issuance or debt raising during the call or transcript. Therefore, based on the available information, there is no indication of any new fundraising through debt or equity at present or in the immediate future.

See what Insecticides India management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Expansion of IIL Biologicals R&D Center planned on a 7-acre shared site, including establishing a new plant and strengthening R&D activities.
  • Continuous strengthening of manufacturing capabilities to support new technology and product development.
  • Focus on all-round development including marketing, sales, and R&D to support growth and premium product launches.
  • Strategic investment in Kaeros acquisition to enable import of raw technical materials, expand B2B segment, and launch a second brand, unlocking new distributor networks.
  • Ongoing development and launch of multiple new products, including biologicals and patented compounds, to increase market presence and profitability.
  • Investment in team building and technology adoption (CRM, training modules) to strengthen sales and technical support teams.

Track Insecticides India — get its next earnings analysis in your feed

How does Insecticides India rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisInsecticides India
Rev 4Mar 3

How does Insecticides India rank in Fertilizers & Agrochemicals?

Compare Insecticides India against every Fertilizers & Agrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →